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Angiogenesis and vasculogenesis: Inducing the
growth of new blood vessels and wound healing
by stimulation of bone marrow–derived
progenitor cell mobilization and homing
Omaida C. Velazquez, MD, Philadelphia, Pa
During embryonic development, the vasculature is among the first organs to form and is in charge of maintaining
metabolic homeostasis by supplying oxygen and nutrients and removing waste products. As one would expect, blood
vessels are critical not only for organ growth in the embryo but also for repair of wounded tissue in the adult. An
imbalance in angiogenesis (a time-honored term that globally refers to the growth of new blood vessels) contributes to
the pathogenesis of numerous malignant, inflammatory, ischemic, infectious, immune, and wound-healing disorders.
This review focuses on the central role of the growth of new blood vessels in ischemic and diabetic wound healing and
defines the most current nomenclature that describes the neovascularization process in wounds. There are now two
well-defined, distinct, yet interrelated processes for the formation of postnatal new blood vessels, angiogenesis, and
vasculogenesis. Reviewed are recent new data on vasculogenesis that promise to advance the field of wound healing.
(J Vasc Surg 2007;45:39A-47A.)It is now well established that an essential part of
normal healing for full thickness cutaneous wounds is the
formation of new blood vessels within the provisional
wound matrix that is referred to as granulation tissue.
Neovascularization of the wound’s granulation tissue oc-
curs by the processes of angiogenesis or vasculogenesis, or
both.1 Angiogenesis refers to the process by which resident
endothelial cells of the wound’s adjacent mature vascular
network proliferate, migrate, and remodel into neovessels
that grow into the initially avascular wound tissue aided by
mature stromal cells such as fibroblasts.1-6 Vasculogenesis is
a de novo process by which progenitor stem cells differen-
tiate and give rise to a replacement vascular network.7-9 It
was once believed that vasculogenesis only occurred during
embryonic life; however, bone marrow-derived endothelial
progenitor cells (BMD EPCs) have been identified in pe-
ripheral blood in adults and participate in new vessel for-
mation.7,10
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BMD EPCs contribute to wound healing because
these progenitor/stem cells are the key cellular effectors
of postnatal vasculogenesis. BMD EPCs given to animals
with surgically induced limb ischemia incorporate into
foci of neovascularization in ischemic muscle, skin, and
wounds.7-13 We have recently identified a critical role for
BMD EPCs in ischemic wound healing.14 We quantified
the contribution of BMD EPCs to wound healing with
and without ischemia in chimeric mice formed using
bone marrow from FVB/Tie-2-LacZ transgenic mice
(FVB/N-TgN[TIE2LacZ]182Sato, The Jackson Labo-
ratory, Bar Harbor, Me). Tie-2-LacZ mice are well
suited for specifically tracking BMD PCs of the endothe-
lial cell lineage because the endothelial-specific Tie-2
promoter is linked to the LacZ reporter gene allowing
cells to be identified by -galactosidase (-gal) expres-
sion.
We used a murine model of hind limb ischemia
induced by femoral ligation/excision (Fig 1) in the
chimeric mice we created (Fig 2, A). Hind limb ischemia
was monitored using laser Doppler flowmetry that allows
for quantifying cutaneous blood flow in the ischemic
relative to the nonischemic hind limb. Hind limb isch-
emia resulted in delayed wound healing (Fig 2, A-C). We
then compared acutely healing wounds in nonischemic
hind limbs with delayed healing wounds in the contralat-
eral ischemic hind limb and correlated healing rates to
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that BMD EPCs play a key role in wound healing and are
recruited into the granulation tissue of rapidly healing
(nonischemic) wounds in significantly greater numbers
than into delayed-healing (ischemic) wounds (Fig 2,
D-G). These studies show that BMD EPCs contribute to
acute wound healing, and the process is deficient or
incomplete at the level of skin wounds in the presence of
severe ischemia.14
In diabetic patients and diabetic murine models, the
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these factors unsuitable to treat diabetic patients with
nonhealing chronic wounds.21-25
HYPEROXIA AS A SAFE CLINICAL TOOL
Systemic hyperoxia induced by hyperbaric oxygen
(HBO2) is a treatment approved by the United States
Food and Drug Administration (FDA) as a safe, adjunc-
tive therapy to stimulate wound healing in diabetic pa-
tients. Patients typically receive 20 treatments with
pure oxygen at 2.0 to 2.4 atmospheres absolute (ATA)
once or twice daily. Controlled trials have shown efficacy
for HBO2 in refractory diabetic wounds, but the mech-
anisms of action are poorly understood.26-31 HBO2 is
not uniformly effective, particularly in diabetic patients
with associated peripheral arterial disease (PAD), ac-
counting for the fact that diabetic/ischemic chronic
nonhealing lower extremity wounds continue to be an
unsolved clinical problem.
Recent investigations from our laboratory indicate that
hyperoxia therapeutically stimulates progenitor/stem cell
release from the bone marrow, but these cells may be
effectively recruited to wounds to enhance vasculogenesis
and healing only if the cytokine milieu in the cutaneous
wound bed is optimized.32-34 Using ischemic and diabetic
murine models, we have recently determined that hyper-
oxia, induced by a clinically relevant HBO2 protocol, in-
creases nitric oxide (NO) levels within femoral bone mar-
row, accelerates the spontaneous revascularization of
surgically induced hind limb ischemia, and increases the
number of BMD PCs in circulation and within cutaneous
hind limb ischemic incisional wounds and diabetic exci-
sional wounds.33,34 These effects appear to be specific to
the release of BMD EPC and responsive to the cytokine
milieu of the wound.33,34
In the ischemic and diabetic murine models that were
used, therapeutic wound-healing effects of increased BMD
EPC mobilization into circulation and recruitment into
wounds were observed in association with enhancement of
neovascularization of the wounds and spontaneous recov-
ery of hind limb perfusion.33,34
ANGIOGENESIS AND VASCULOGENESIS IN
WOUND HEALING
It is increasingly evident that wound healing occurs
because of events in two compartments. Within the bone
marrow, various signaling pathways lead to mobilization
of BMD EPCs and other progenitor/stem cells involved
in the healing cascade. Within the wound, neovascular-
ization occurs because of local factors that stimulate
adjacent cells (angiogenesis) and because of recruited
circulating BMD EPCs that contribute to existing and
new vascular channels (vasculogenesis). Vascular main-
tenance, repair, and wound-healing cellular and molec-
ular cascades at the level of both the bone marrow and
within the peripheral wound are compromised by diabe-tes as a result of BMD EPC impairments.15-20 The use of
cytokines and growth factors such as GM-CSF and
VEGF-A to stimulate the bone marrow release of pro-
genitor stem cells for purposes such as wound healing or
therapeutic neovascularization has been considered, but
generalized application has been thwarted because of
risks such as acute arterial thrombosis, angina, hypoten-
sion, sepsis, and death.21-25,35
Overall, normal cutaneous wound healing proceeds
through an orderly sequence of steps that require the
control of contamination and infection, resolution of in-
flammation, regeneration of the connective tissue matrix,
angiogenesis/vasculogenesis, wound constriction, and re-
epithelialization. Chronic wounds are those that have failed
to follow this sequence and do not achieve a sustained
anatomic and functional result.36
The hypoxic nature of all wounds has been demon-
strated, but when hypoxia is pathologically increased,
wound healing is impaired and the rate of wound infection
increases.35-40 Local oxygen tensions in the vicinity of the
wound are approximately half the values observed in nor-
mal, unwounded tissue.41 Fibroblast replication, collagen
deposition, angiogenesis, vasculogenesis, and intracellular
leukocyte bacterial killing are oxygen-sensitive responses
essential to wound healing.33,34,39,42-44 For these reasons,
a number of investigators have examined the role of hyper-
oxia in wound healing.26-31,45 This area remains an open
field for investigation because, for the most part, chronic
wounds are (to this date) a major unsolved clinical prob-
lem.
THE UNSOLVED CLINICAL PROBLEM OF
LOWER EXTREMITY CHRONIC WOUNDS
It has been estimated that up to 2 million Americans
have nonhealing lower extremity wounds that account
for 162,500 annual hospitalizations and $1 billion per
year in health care costs in the United States.46-48 Most
are the result of diabetes alone or with arterial insuffi-
ciency, venous stasis, and neuropathy. These chronic
wounds are more common in women, elderly patients,
diabetic patients, and African American patients, and
result in diminished quality of life, limb loss, and in-
creased morbidity and mortality. In diabetic patients,
morbidity due to chronic wounds is staggering, with
more than half of all lower limb amputations in the
United States occurring in patients with diabetes.
Diabetes is reaching epidemic proportions in West-
ern societies, and is predicted to affect 300 million
people worldwide by 2025.49,50 Nearly 800,000 new
cases of diabetes mellitus are diagnosed each year in the
United States, and a lower extremity ulcer will develop in
approximately 15% of patients at some point in their
lives.51-54
The pathophysiology of diabetic lower extremity
ulcerations and delayed healing has been well described.
Contributing factors include progressive development of
asensory, vasomotor, and autonomic neuropathy leading
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ties that increase plantar foot pressure, and alterations in
autoregulation of dermal blood flow. Diabetic patients
show earlier development and progression of lower ex-
tremity peripheral arterial occlusive disease (PAD), with
a predilection for the trifurcation level of vessels just
distal to the knee.
In addition, the tissue microcirculation is severely dis-
eased (microangiopathy), even in patients with patent
proximal vessels. Some of these vascular complications in
diabetes, as well as the healing defects, have been associated
with a decrease in number and function of circulating BMD
EPC.15-20 Impaired host responses to infection and other
cellular dysfunctions also contribute to the refractory na-
ture of diabetic wounds. About 20% of diabetic lower
extremity ulcers have arterial flow insufficiency as their
primary etiology, approximately 50% will have primary
diabetic neuropathy, and about 30% will have both condi-
tions.53,55
Even after correction of large blood vessel dysfunction
by open surgical or endovascular revascularization, only
about 47% of patients will heal in a span of 20 weeks with
standardized treatment including glycemic control,
débridement of necrotic tissue, control of infection, use of
moist dressings, protection from pressure or trauma related
to ambulation, and adjuvant HBO2 therapy.
26,56-58
Hyperbaric oxygen therapy is currently a clinical
adjunctive therapy used to stimulate wound healing in
situations where the microvasculature has become atten-
uated but when the large inflow vessels remain open or
have been revascularized. Pronounced tissue-level hy-
peroxia is the main effect of HBO2 treatments, which are
known to raise arterial oxygen tension to several thou-
sand Torr and tissue oxygen tension to about 300
Torr.59 The effectiveness of HBO2 as an adjuvant clinical
therapy for the treatment of diabetic lower extremity
ulcerations has been supported in evaluations by a grow-
ing number of studies.57,60-65 The clinical protocols in
current use are not always effective and were arbitrarily
determined because fundamental mechanisms are un-
known. Thus, it is hoped that ongoing research in this
area will yield optimization of the protocols, or reduc-
tion of the nonresponder rate, or both.
MOBILIZATION OF STEM CELLS FOR
ANGIOGENESIS, VASCULOGENESIS, AND
WOUND HEALING
Studies in mice, from our laboratory and others, indi-
cate that the marrow is likely to be a central source for
mobilized progenitor/stem cells.32-34,66,67 Emigration of
cells from the bone marrow is generally thought to occur
after a period of cell proliferation within the marrow
niche.68-70 In addition, the reported evidence also indicates
a rapid mobilization of stem cells, which suggests that cell
proliferation is not always necessary. In mice, infusion of
soluble Kit ligand (the soluble portion of the c-Kit recep-
tor) triggers mobilization of CD34 cells in 1 hour.71There was a fourfold elevation in circulating progenitor
cells within 10 minutes when human volunteers were sub-
jected to highly strenuous exercise.72
Data also indicate that specialized microenvironments
exists in the marrow where stem/progenitor cells exhibit
different propensities for proliferation and mobilization
and from where matrix metalloproteinase-9 (MMP-9) ac-
tivity mediates BMD EPC release.73-75 From our find-
ings32-34 and reports by Nakamura et al71 and Rehman et
al,72 it appears a subpopulation of BMD EPCs exist within
specialized bone marrow niches that are poised for rapid
release to the circulation.
Nitric oxide has been shown to play a central role in the
bone marrow mobilization and release of EPC.76 Because
hyperoxia, induced by HBO2 increases nitric oxide syn-
thase (NOS) activity in cerebral cortex tissue, perivascular
pulmonary tissue, and neutrophils,77-79 we began to study
whether HBO2 may initiate stem/progenitor cell release by
NO-mediated mechanisms. We recently reported that in
mice and patients, HBO2 increases the number of circulat-
ing progenitor stem cells and BMD EPC32,33 (Figs 3, 4,
and 5).
Mice were exposed to sham pressurization (placed in
the hyperbaric chamber flushed with air at ambient pres-
sure) or to O2 at 1 ATA or 2.4 ATA for 90 minutes.
There was no deviation in circulating cells observed in
mice exposed to sham pressurization or 1 ATA O2, but
significant effects occurred in those exposed to 2.4 ATA
O2 (Fig 3).
32,33 Scatter dot-plots and histograms (Fig 3,
A) exhibit the elevation in the CD34 and stem cell
antigen-1 (Sca-1) cell populations in a representative
control mouse, at 16 hours after exposure to 2.4 ATA
O2, and in a mouse pretreated with NG-nitro-L-arginine
methyl ester (L-NAME), a nonspecific NOS inhibitor
before HBO2 (Fig 3, B shows the quantification in 22
mice). These data indicate that HBO2 stimulates stem
cell release from the mouse bone marrow by a NO-
mediated mechanism. This hyperoxia-induced mobiliza-
tion of progenitor/stem cells from the bone marrow is
highly specific to the release of BMD EPCs and is
associated with a therapeutic vasculogenesis and wound-
healing response.33
The mobilized primitive cells appear to be functional.
The HBO2-mediated elevation in circulating Sca-1/
CD34 cells results in an increase in the colony-forming
cell capacity of circulating cells. As shown in Fig 4, there is
a significant elevation in the colony-forming cell capacity
after exposure to HBO2 that is inhibited by pretreatment
with L-NAME. Again, these data strongly suggests that
hyperoxia augments mobilization of functional stem/pro-
genitor cells into the circulation by a NO-mediated mech-
anism. In fact, direct, real time measurements in fluctua-
tions of bone marrow NO levels show that bone marrow
NO level drastically rises in response to hyperoxia, an effect
completely inhibited by L-NAME.33
The number of circulating stem/progenitor cells express-
ing the progenitor cell CD34 epitope is also clearly increased
by HBO2 in human subjects
32 (Fig 5). The expression of the
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tor/stem cells of hemangioblast lineage, which give rise to
hematopoietic and endothelial progenitors.80 There was a
significant increase in CD14/CD34 cells after HBO2 in all
five patients evaluated in our pilot studies.32 Fig 5 shows data
from one representative patient before and after the first and
10th hyperoxia treatments. The number of dually positive
cells (CD14/CD34) remained elevated in all patients before
Fig 3. A, Scatter-plots and histograms for stem cell antig
an air-exposed, control mouse; a mouse sacrificed 16 hou
first injected with the nonspecific nitric oxide synthase
mg/kg), 30 minutes before exposure to hyperbaric oxy
exhibit cells from three quadrants of the scatter diagram
were gated for small lymphocytes and scans were obtain
CD34 and Sca-1 cells in peripheral circulation of mice.
after exposure to HBO2 at 2.4 ATA for 90 minutes, at 1
before HBO2. The number of mice included in each gro
variance). Data and modified figure reprinted with per
Fluorescein isothiocyanate conjugated.
Fig 4. Colony-forming cell (CFC) capacity of monocytes from
blood with or without hyperbaric oxygen treatment as designated.
Mice were sacrificed 16 hours after hyperbaric oxygen exposure for
90 minutes (n 5 mice/group. *P  .05 (analysis of variance.
L-NAME; NG-nitro-L-arginine methyl ester. (Data and modified
figure reprinted with permission from Thom et al.32)and after the 10th and 20th treatments.32 These initial humanstudies show that a population of monocytes in peripheral
blood coexpressing the hemangioblast progenitor/stem cell
marker CD34 and the myeloid marker CD14 is increased in
response to HBO2.
32
Moreover, using transgenic mice and a bone marrow
transplantation model that allows us to specifically track BMD
EPC,33 we showed that these hyperoxia effects on progeni-
tor/stem cell release are highly specific to mobilization of
BMD EPC. The increased systemic release of BMD EPC into
circulation improves neovascularization and wound healing in
murine ischemic excisional hind limb wounds.33 Hyperoxia,
induced by HBO2 daily treatments (2.4 ATA O2 for 90
minutes) improves hind limb perfusion by laser Doppler flow-
metry after femoral ligation/excision, in mice, and by day 8
after wounding, the ischemic excisional punch biopsy wounds
treated daily with HBO2 heal significantly faster.
33 These
effects on BMD EPC mobilization, vasculogenesis, and
wound healing were not observed in mice that received treat-
ment with L-NAME before HBO2, indicating that the im-
provements in BMD mobilization, vasculogenesis, and
wound healing are mediated by NO.
Mobilized progenitor cells can differentiate in situ to
form capillary networks.7,81 Many chemokines and cyto-
kines trigger stem/progenitor cell release by induction
of MMP-9 in bone marrow, and NO is clearly linked to
these processes.73-76 Using VEGF-A as a proximal stim-
ulus, Aicher et al76,82 demonstrated that endothelial
NOS becomes activated in bone marrow stroma, NO
(Sca-1)/CD34-expressing cells in peripheral blood from
er exposure to 2.4 ATA O2 for 90 minutes, and a mouse
itor, NG-nitro-L-arginine methyl ester (L-NAME; 40
HBO2) and killed 16 hours after exposure. Histograms
luding only those cells in the lower left quadrant. Plots
y counting 50,000 gated events. B, Mean elevations of
are mean standard error for control mice, immediately
rs post-HBO2, and in mice first injected with L-NAME
e indicated by (n) in the columns, *P  .05 (analysis of
on fromThom et al.32 RPE, R-phycoerythrinis; FITC,en-1
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kine, soluble Kit ligand. This agent shifts endothelial
progenitor and hematopoietic stem cells from a quies-
cent to the proliferative niche and stimulates rapid stem
cell mobilization to the peripheral blood.12,71,73-76,82 It
has been demonstrated that in the setting of trauma and
ischemia, systemic VEGF-A levels rise following a time
course that mirrors the rise in circulating BMD EPC.
Until recently,33 it was unknown if hyperoxia (acting
through similar mechanisms as hypoxia/ischemia or
VEGF-A; that is, acting by NO synthesis), can modulate
these same angiogenic and vasculogenic signal cascades.
HOMING OF BONE MARROW–DERIVED
ENDOTHELIAL PROGENITOR CELLS TO
PERIPHERAL CUTANEOUS WOUNDS
The chemokine SDF-1 mediates migration and
homing of stem cells, is up-regulated by tissue hypoxia in
response to VEGF-A, and serves as the key homing signal
guiding BMD EPCs into areas of ischemia (ie, hypoxic
tissue).37,83,84 In healing cutaneous wounds, SDF-1
may function as a homeostatic regulator of tissue remod-
eling.85 Its role in promoting wound healing in chronic
skin wounds (eg, wounds in diabetic patients or PAD)
remains mostly unknown. Most recently, we studied this
topic in the streptozotocin diabetic murine model.34
Streptozotocin treatment renders mice chemically hypo-
insulinemic by causing ablation of the pancreatic Islets of
Langerhans, and they can be used to study delayed wound
healing in a type 1 diabetes model.86 The wound-healing
impairment can be furthered exacerbated by ischemia induced
by surgical femoral artery excision.1,14 SDF-1 mediates
BMD EPC homing through its receptor CXCR4.37 At the
unwounded tissue level, EPC recruitment depends on isch-
emia-induced or hypoxia-induced upregulation of SDF-1.37
Until recently, the role of SDF-1 in diabetes-related de-
layed healing and in PAD remained mostly unknown. We
analyzed the cutaneous wounds of streptozotocin-diabetic
mice and were intrigued to determine that the baseline
levels of cells staining positive for SDF-1 are significantly
Fig 5. Flow cytometry data from one patient before and
Similar results were observed in other patients and in iscdecreased in the diabetic wounds.34 Not surprisingly, thestreptozotocin-diabetic mice showed decreased cutaneous
wound closure rates.34
Our data indicate that the diabetic impairments in
BMD EPC recruitment can be therapeutically addressed by
improving the cytokine milieu of the wound and could
potentially be further synergistically impacted by a systemic
therapy (eg, hyperoxia) that aims at increasing the circulat-
ing pool of BMD EPCs.
The data also indicate that hyperoxia increases wound
closure rates in the ischemic and the diabetic murine mod-
els, likely by significantly augmenting the circulating pool
of BMD EPCs and impacting both angiogenesis and vas-
culogenesis. NOS inhibition blocks these hyperoxia-in-
duced therapeutic effects.33,34 Hyperoxia alone does not
have a significant impact on BMD EPC homing to wounds
with delayed healing.
On the basis of these recent findings, it is our current
working hypothesis that hyperoxia induces the release of
BMD EPCs into circulation by NO mechanisms (eNOS/
NO) and that these crucial reparative and vasculogenic
cells may then be recruited into wounds in increased
numbers by virtue of their hyperoxia-induced activation
and their increased numbers within the blood pool;
however, local wound interventions that enhance EPC
homing (such as increasing level of EPC homing chemo-
chine, SDF-1) may be crucial for optimal therapeutic
recruitment of these progenitor cells to diabetic and
ischemic wounds.34
CONCLUSIONS
BMD EPCs are the newest cellular target that may be
used to influence postnatal angiogenesis and vasculogen-
esis. Recent data demonstrate that intermittent systemic
hyperoxia induced by FDA-approved HBO2 protocols
may be a currently available, safe, and clinically useful
tool to enhance BMD EPC mobilization into circulation
with minimal if any side effects. Other approaches for
systemic progenitor/stem cell mobilization that involve
the systemic use of cytokines or growth hormones may
carry significant associated side effects related to intra-
the first and 10th hyperbaric oxygen (HBO2) treatment.
c and diabetic murine models.32-34afterarterial thromboses (GM-CSF) or leaky capillary syn-
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circulation by hyperoxia can effectively be recruited to
delayed-healing cutaneous wounds (affected by diabetes
or ischemia, or both), or whether local wound treat-
ments such as SDF-1 may achieve synergism with hy-
peroxia in regards to the BMD EPC recruitment to
compromised cutaneous wounds in diabetic patients,
will require further study.
We have determined that hyperoxia-mobilized progen-
itor cells may be effectively recruited into murine diabetic
or ischemic wounds to enhance wound angiogenesis, vas-
culogenesis, and healing. Because there is no uniformly
effective method to achieve healing in wounds compro-
mised by diabetes and ischemia, and because these chronic
wounds represents such a profound, unsolved, and rapidly
increasing health problem with exuberant morbidity, mor-
tality, and cost, we believe that this area of research may
continue to be fruitful. For example, the delineation of the
signals that mediate the hyperoxia-induced progenitor cell
release from the bone marrow (upstream and downstream
from activation of NOS/NO) will constitute a leap forward
in our basic understanding of the biology of BMD EPC
mobilization. This latter knowledge may become a strong
foundation for further novel targets of therapeutic inter-
vention.
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